



**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL**

Submit an original, and a duplicate for fee processing
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

RECEIVED
SEP 17 2001
TECH CENTER 1600/2900
CPA/11646

Commissioner for Patents
Box CPA
Washington, DC 20231

Attorney Docket No.: 1268-073A
First Named Inventor: Shai YARKONI
Express Mail Label No.:
Total Pages:

This is a request for a application under 37 CFR 1.53(d).
(continued prosecution application (CPA)) of prior application number 09/147,346, filed on
December 4, 1998, CHIMERIC TOXINS FOR TARGETED THERAPY.

1. ☐ Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application.
2. ☒ A preliminary amendment is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
 - a. ☐ DELETE the following inventor(s) named in the prior nonprovisional application:
 - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5.
 - a. ☐ PTO-1449
 - b. ☐ Copies of IDS Citations

	NO. OF CLAIMS		EXTRA CLAIMS	RATE	FEE
Total Claims	18	MINUS 20	0	x \$18 =	\$ 0.00
Independent Claims	2	MINUS 3	0	x \$80 =	\$ 0.00
Basic Application Fee					\$ 710.00
Extension of time					\$390.00
Total Application Fee					\$ 710.00
Subtract 1/2 if small entity					\$355.00
TOTAL APPLICATION FEE DUE					\$ 745.00
AMOUNT ENCLOSED					\$745.00

6. Small entity status
 - a. ☒ Small entity has been established
 - b. ☐ Is no longer claimed

09/14/2001 CHNGUYEN 00000069 09147346 355.00 0P
01 FC:231

7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 07-1337;
- a. ☒ Fees required under 37 CFR 1.16.
 - b. ☒ Fees required under 37 CFR 1.17.

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

Respectfully submitted,

LOWE HAUPTMAN GILMAN & BERNER, LLP



Michael G. Gilman
Registration No. 19,114

USPTO Customer No. 22429
1700 Diagonal Road, Suite 310
Alexandria, Virginia 22314
(703) 684-1111
(703) 518-5499 Facsimile
Date: September 13, 2001
MGG/vgg



RECEIVED

SEP 17 2001

TECH CENTER 1600/2900

TECH CENTER 1600/2900

SEP 17 2001

RECEIVED

Docket No.: 1268-073

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Shai YARKONI, et al.

Serial No. 09/147,346

Filed: December 4, 1998

For: CHIMERIC TOXINS FOR TARGETED THERAPY

Group Art Unit: 1646

Examiner: L. Helms

PRELIMINARY AMENDMENT

HONORABLE ASSISTANT COMMISSIONER

FOR PATENTS

Washington, D. C. 20231

Sir:

In advance of continued prosecution, kindly amend the above identified patent application as follows:

IN THE CLAIMS:

Kindly amend the following claims as indicated:

1. (Four times amended) Targeted fused chimeric toxins comprising a genetically engineered molecule produced by fusing, at the level of cDNA;

A. at least one cell targeting moiety encoding GnRH or GnRH analog that is adapted to recognize specific cells bearing gonadotropin releasing hormone binding sites; and

10/26/01
not
w/22
10/26/01

F-1
2-6
H-1

#23/F
KD
9-25-01